Omnaris

Treatment for Allergic Rhinitis

Altana Submitted New Drug Applications For Ciclesonide Nasal Spray in the U.S. and Canada; Major Milestone in Broadening the Ciclesonide Product Platform

BAD HOMBURG/KONSTANZ, Germany -- March 7, 2006 - Altana AG announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the company's new drug application (NDA) for Ciclesonide nasal spray. A new drug submission (NDS) for Ciclesonide nasal spray was also submitted to the Canadian authority Health Canada. Altana is seeking marketing approval for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis.

"The submissions of Ciclesonide nasal spray represent a major milestone for us, as they reinforce our commitment to providing innovative treatments for respiratory diseases," said Dr. Hans-Joachim Lohrisch, Member of the Board of Altana AG and Chief Executive Officer of Altana Pharma.

Intranasal corticosteroids are considered to be the gold standard for the treatment of allergic rhinitis, and they work by reducing inflammation - the major underlying cause of nasal symptoms.

The clinical development program for Ciclesonide nasal spray leading to submission in the U.S. and Canada was performed by Altana Pharma U.S. Acceptance for filing by the FDA does not mean that the NDA has been or will be approved, nor does it represent an evaluation of the adequacy of the data submitted.

Ciclesonide: A broader product platform

Besides the nasal spray, Ciclesonide is the active substance of an inhaled corticosteroid, that is already approved in 35 countries worldwide for the treatment of persistent asthma. A new drug application has also been filed with the U.S. FDA. In addition the Ciclesonide platform will also include a fixed combination product with a long-acting beta-agonist, currently in phase II of clinical development. Altana partners with Sanofi-Aventis in the United States and with Teijin in Japan on various Ciclesonide based products.

About Allergic Rhinitis

Allergic rhinitis is a chronic inflammatory disease of the nasal mucosa causing sneezing, itching, nasal congestion, and discharge. Seasonal allergic rhinitis is caused by substances that trigger allergies and is sometimes referred to as hay fever. Perennial allergic rhinitis is a chronic condition caused by triggers such as pet dander and dust. The result of poorly controlled allergies can result in impairments in day-to-day activities as well as a reduction in a patient's quality of life. According to the American Academy of Allergy, Asthma, and Immunology, more than 40 million Americans are currently estimated to suffer with allergic diseases and allergies are the sixth leading cause of chronic disease in the United States.

Source: Altana AG

Posted: March 2006

Related Articles

Omnaris (ciclesonide) FDA Approval History

View comments

Hide
(web2)